Agfa signs up Inphact to supply CR, PACS via ASP
Agfa signs up Inphact to supply CR, PACS via ASPAgfa has signed a purchase and supply agreement with Nashville, TN-based Inphact to provide Agfa CR and PACS products, service, and support to community hospitals and clinics on an application
Agfa signs up Inphact to supply CR, PACS via ASP
Agfa has signed a purchase and supply agreement with Nashville, TN-based Inphact to provide Agfa CR and PACS products, service, and support to community hospitals and clinics on an application service provider basis. Through its ASP service, Inphact enables imaging departments to rent its technology platform, which includes digital acquisition equipment, information software, image distribution, and the archive. Customers are charged on a per-procedure basis. Inphact says this latest contract with Agfa will be worth at least $5 million over the next 14 months.
In related news, Agfa has taken a majority position in RIS vendor Quadrat. The two Belgian firms now plan to accelerate the integration of RIS technology into Agfas Impax PACS product and pursue further development of electronic patient record technologies.
- Search Again
- Return To HNN Homepage
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
